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Abstract
Background:  Basic research of gefitinib (Iressa, ZD1839) has demonstrated the
combination effects of gefitinib and chemotherapy were sequence-dependent. To
evaluate the efficacy of sequential administration of gefitinib following a minor response
or partial response to two to three cycles of chemotherapy, a phase II clinical trial was
done in Chinese patients with advanced non-small-cell lung cancer (NSCLC).
Methods: Thirty-three consecutive patients with advanced NSCLC that had been
pretreated with at least one chemotherapeutic regimen and were responding to
chemotherapy following 2 to 3 cycles of treatment, entered the trial from May 2004 to
February 2006. Patients received gefitinib at an oral dose of 250 mg once daily for 4
weeks.
Results: Thirty-three patients were evaluable for response and toxicity. The objective
response rate was 24.2% (8 of 33)(95% CI, 11% to 42%). The symptom improvement
rate was 54.5% (18 of 33) (95% CI, 41% to 69%). The median duration of response was
7 months (95%CI, 4.0 to 13.2 months). The median time to disease progression (TTP)
was 6.5 months (95%CI, 0.7 to 16.6 months). The median overall survival time (OS) was
9.8 months (range, 2.1 to 18.0 months), and the actuarial 1-year survival was 36.4%.
Toxicity was relatively mild and included only one patient (3.0%) with grade 4 diarrhea,
1 (3.0%) with grade 3 rash, 1 (3.0%) with grade 3 nausea, and 1 with grade 3 vomiting
(3.0%).
Conclusion:  Preliminary results suggest that sequential administration of gefitinib
following a response to chemotherapy may be beneficial for Chinese patients with
advanced NSCLC. Further randomized clinical trials are needed.
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Background
Despite the use of platinum-based combination chemo-
therapy, which has shown to prolong survival in patients
with advanced non-small-cell-lung cancer (NSCLC) when
compared to best supportive care, the prognosis of
advanced NSCLC continues to be poor with a median sur-
vival of about 10 months [1,2]. The goals of chemother-
apy are to palliate symptoms, improve quality of life
(QOL), and prolong survival. Treatment-related toxicities
resulting in impaired QOL are major concerns for combi-
nation chemotherapy [3,4]. Second line treatment
options, including docetaxel, pemetrexed, and erlotinib,
have been approved in the United States for patients who
failed to platinum-based chemotherapy, but they have
limited efficacy and potentially considerable toxicity
[5,6]. More treatment options are needed for patients with
advanced NSCLC.
Gefitinib (Iressa, AstraZeneca, Alderley Park, Macclesfield,
United Kingdom) is a synthetic anilinoquinazoline com-
pound that inhibits epidermal growth factor receptor
(EGFR) tyrosine kinase in vitro at nanomolar concentra-
tions [7]. Several clinical studies have demonstrated the
antitumor activity of gefitinib, with response rates ranging
from 9% to 20% even in the second and the third line set-
tings [8,9]. Impressively, improvement in tumor-related
symptoms was observed in nearly 40% of patients, and
often within days of starting gefitinib therapy [8-10]. Two
combination trials with gefitinib, INTACT 1 and 2, count-
ing over 2,000 enrolled patients, failed to demonstrate
any improvement in overall survival (OS), time to disease
progression (TTP), and response rates (RR) with the gefit-
inib combination compared to standard chemotherapy
[11,12]. However, previous preclinical studies had dem-
onstrated that concomitant administration of gefitinib
and chemotherapy could render tumor cells less sensitive
to chemotherapy, whereas, sequential regimens with
gefitinib administration following chemotherapeutic
agents, such as oxaliplatin or CPT-11, enhanced and
maintained cell damage from chemotherapy [13-15].
Based on our clinical experience, response is usually
apparent after the initial two to three cycles of chemother-
apy.
Therefore, the present open-labeled, nonrandomized
phase II trial was performed to evaluate the clinical effi-
cacy and toxicity of sequential administration of gefitinib
following a minor response or partial response to chemo-
therapy in advanced NSCLC.
Methods
Patient eligibility
All the patients enrolled in this study had histologically
confirmed, measurable, locally advanced or metastatic
NSCLC. Measurable disease had to be completely outside
the radiation portal. Patients with stable brain metastases
were eligible. Different chemotherapy regimens were
allowed, as long as a minor response (MR), or partial
response (PR) was obtained after two to three cycles of the
last chemotherapeutic regimen. Gefitinib was started
within 3 days of the response evaluation for the last cycle
of chemotherapy. Patients were older than 18 years of age,
and had an Eastern Cooperative Oncology Group
(ECOG) performance status (PS) of 0 to 3, a life expect-
ancy of 12 weeks or longer, a WBC count ≥ 3.0 × 109/L,
platelet count ≥ 100 × 109/L, bilirubin less than 1.5-fold
of the upper limit of normal (ULN), ALT or AST less than
three-fold of the upper limit of institutional reference
value (elevated to five-fold of the ULN in patients with
known hepatic metastases), and a calculated creatinine
clearance rate of more than 45 mL/min. Patients with a
history of other malignancies were not eligible for treat-
ment. All patients provided written informed consent
before chemotherapy, and trial document approval was
obtained from the ethics committee before study registra-
tion.
Treatment plan
Gefitinib was administered at 250 mg once daily in the
morning or afternoon, at approximately the same time,
and continued until disease progression. Before initiation
of treatment, all the patients underwent a complete phys-
ical examination, their medical history was taken and
blood count, serum biochemistry tests (hepatic and renal
function tests and electrolytes), urinalysis, and echocardi-
ogram performed; a chest x-ray and computed tomogra-
phy (CT) or magnetic resonance imaging (MRI) scans of
all disease sites were obtained during the 3 weeks prior to
study entry. Systemic anticancer therapy was not permit-
ted during the trial, except for palliative radiotherapy in
patients with isolated symptomatic bone metastases.
Treatment assessment
Disease staging and response were assessed by clinical
examination, chest x-ray, and computed tomographic
(CT) scans. Bidimensionally measurable disease was eval-
uated by imaging procedures (chest x-ray, ultrasonogra-
phy, CT scanning, magnetic resonance imaging).
Response assessments were performed every 4 weeks and
confirmed by a repeat measurement no less than 4 weeks
from the first claim of a response. We assessed objective
tumor response as complete response (CR), partial
response (PR), stable disease (SD), or progressive disease
(PD) in accordance with the standard WHO response cri-
teria [16]. TTP was defined as the interval from initiation
of gefitinib to disease progression, and OS was defined as
the interval from initiation of responding chemotherapy
until death.BMC Cancer 2006, 6:288 http://www.biomedcentral.com/1471-2407/6/288
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Disease-related symptom improvement was measured
using the Lung Cancer Subscale (LCS), a validated sub-
scale of the QOL instrument, of the Functional Assess-
ment of Cancer Therapy-Lung (FACT-L) questionnaire
[17].
Toxicities were graded according to the National Cancer
Institute Common Toxicity Criteria (NCI-CTC) version
2.0 before each therapy course.
Statistical analysis
The objective response rate was determined with 95%
confidence intervals. TTP, and OS were analyzed with the
Kaplan and Meier method [18]. All reported P values were
generated from a two-sided analysis via the SPSS 11.0 sys-
tem (SPSS, Inc, Chicago, IL).
Results
Patient characteristics
Between May 2004 and February 2006, a total of 33 con-
secutive patients who obtained PR or MR after last chem-
otherapy from 106 NSCLC patients entered the study.
Characteristics of the eligible patients are listed in Table 1.
All 33 patients were evaluable for both response and tox-
icity. The median age was 58 years (range from 31 to 72).
Most of the patients were male (66.7%). Ten patients
(30.3%) had stage IIIb disease, and 23 (69.7%) had stage
IV disease at study entry. Six patients (18.2%) had PS ≥ 2,
and 23 patients (69.7%) had at least one measurable met-
astatic lesion. Thirteen (39.4%) had failed one prior
chemotherapy regimen; 8(24.2%) failed to respond to at
least two prior regimens; all the 21 pretreated patients had
failed to at least one line of platinum-based chemother-
apy; only 12(36.4%) patients had been chemotherapy-
naïve prior to the most recent chemotherapy regimen.
Before gefitinib, 6 (18.2%) received docetaxel alone, the
other 27 (81.8%) received platinum-based regimen.
Twenty-six patients (78.8%) achieved PRs, 7 (21.2%)
achieved MRs after 2 or 3 cycles of chemotherapy. Five
patients (15.2%) had undergone prior surgery with cura-
tive intent. Fourteen (42.4%) of them were smokers. Most
of the non-smokers were female. Twenty-three had aden-
ocarcinomas (69.7%) and 14 of them were male patients.
Efficacy and survival
Gefitinib was administered, with a median treatment
duration of 6.5 months (95%CI, 1 to 16.6 months). The
overall RR was 24.2% (8 of 33) (95% CI, 11% to 42%).
There were 7 PRs (21.2%) and one CR (3%). Stable dis-
ease was recorded in 69.7% (23 patients) and progressive
disease in 6.1 % (2 patients) (Table 2). The overall disease
control rate, including CR, PR and SD, was 93.9%. A com-
parable response rate was observed for adenocarcinoma
and squamous carcinoma patients as 8 of the 24 patients
with adenocarcinoma had a major objective response
(33.3%), while none of the 9 patients with squamous car-
cinoma had a major objective response. Rapid tumor
regression was demonstrated for most of the responders.
Among these responders, 7 patients (87.5%) obtained an
objective response as measured by the first post-baseline
assessment. One patient met the response criteria in the
second month. Responses, including partial and/or com-
plete responses, were observed at all sites of disease such
as primary tumor, liver, and lymph node metastases.
The median duration of response was 7 months (95%CI,
4.0 to 13.2 months); the median time to disease progres-
sion was 6.5 months (95%CI, 0.7 to 16.6 months) (Fig 1),
the median OS was 9.8 months (range, 2.1 to 18.0
months) (Fig 2). Eleven patients (33.3%) were dead after
a median follow-up of 10 months (95%CI, 2.1 to 18.0
months). The actual 1-year survival rate was 36.4%. There
was no significant difference in the response rate, dura-
tion of response, or OS according to performance status.
However, patients with stage IIIb disease had a tendency
toward longer OS compared to those with stage IV disease
(P = 0.061).
Table 1: Characteristics of the patients
Characteristic Value
Age, years
Median 58
Range 31–72
Sex
Male 22(66.7)
Female 11(33.3)
ECOG performance status
0 13(39.4)
1 14(42.4)
25 ( 1 5 . 2 )
3 1(3.0)
Smoking History
Smoker 14(42.4)
Non-smoker* 19(57.6)
Histology
Adenocarcinoma 24(72.7)
Squamous cell carcinoma 9(27.3)
Stage at study entry
III B 10(30.3)
IV 23(69.7)
No. of Prior failed chemotherapy regimen
0 12(36.4)
1 13(39.4)
≥28 ( 2 4 . 2 )
Chemotherapy response prior to gefitinib
MR 7(21.2%)
PR 26(78.8%)
*Non-smoker = patients who had smoked less than 100 cigarettes in 
their lifetime.BMC Cancer 2006, 6:288 http://www.biomedcentral.com/1471-2407/6/288
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Disease-related symptom improvement and toxicity
All 33 patients were assessable for toxicity and symptom
improvement. Improvements in disease-related symp-
toms are shown in Table 3. The symptom improvement
rate was 54.5% (18 of 33)(95% CI, 41% to 69%) in
patients with a tumor response, and 36.3% (95% CI,
20%–55%) in patients without a response. The difference
was not statistically significant (χ2  test: P = 0.182).
Although AEs existed in this study, therapy was well toler-
ated. Toxicity was mainly mild (CTC. G1 or G2). G3 and
G4 toxicity was uncommon, and most events were revers-
ible (Table 4). Drug-related AEs were observed in 30.3%
of patients. Only grade 3 and grade 4 AEs required a short
treatment interruption, and none required a dose reduc-
tion. No drug-related deaths occurred. Twenty-three
patients (69.7%) were either asymptomatic or showed no
worsening of their symptoms during the study. The severe
drug-related G3 or G4 AEs including diarrhea, vomiting
and nausea only occurred in one patient who had to be
hospitalized for severe diarrhea. None of the patients was
withdrawn from the trial due to AEs.
Discussion
This paper describes the first phase II trial of sequential
administration of gefitinib following tumor responses to
chemotherapy in patients with advanced NSCLC. The TTP
and OS observed are encouraging, although patient selec-
tion bias cannot be excluded. It is unclear whether having
achieved a response from chemotherapy influences the
efficacy of subsequent gefitinib. It should be noted that
the TTP and OS registered in this study are comparable to
historical data obtained in patients who received first-line
chemotherapy for six cycles [4,19,20]. Although chemo-
therapy had administered two or three cycles at the physi-
cian's discretion, the TTP in this study is comparable to
the duration of response of continuous chemotherapy
reported in the literature. Furthermore, the calculations of
OS in continuous chemotherapy and in sequential gefit-
inib are both from the start of responding chemotherapy
until death.
To date, second-line chemotherapy has only shown mod-
est efficacy in advanced NSCLC with overall RRs ranging
from 6% to 25%, median duration of response ranging
from 1.2 months to 7.5 months, and median OS ranging
from 3.2 months to 9.5 months [4,20,22-24]. Previous
studies indicated that second-line chemotherapy mainly
plays a palliation role in advanced NSCLC. The QOL
Overall survival of 33 patients treated with gefitinib Figure 2
Overall survival of 33 patients treated with gefitinib.
Time to progression of 33 patients treated with gefitinib Figure 1
Time to progression of 33 patients treated with gefitinib.
Table 2: Response in 33 Assessable Patients
Response All Patients
No. %
Complete response 1 3
Partial response 7 21.2
Stable disease 23 69.7
Progressive disease 2 6.1
Total 33 100BMC Cancer 2006, 6:288 http://www.biomedcentral.com/1471-2407/6/288
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improvement in chemotherapy is mainly dependent on
its efficacy. Patients with advanced NSCLC usually have
an extremely poor prognosis and exhibit severe symptoms
if their tumor progresses after chemotherapy. Therefore,
this trial sought to increase or maintain the efficacy of
chemotherapy by adding gefitinib after tumors responded
to chemotherapy.
Some evidence had demonstrating that chemosensitivity
is mainly related to the proliferative activity of tumor cells
and reductions of the proliferation rate are associated with
chemoresistance [12,25]. In this regard, chemotherapy is
more effective in tumors with higher proliferative rates.
The clinical efficacy of chemotherapy could be influenced
by the simultaneous administration of gefitinib, which
leads to a decrease in growth factor signaling. Further-
more, our previous in vitro studies reported that the
sequential administration of EGFR inhibitors after chem-
otherapy may enhance/maintain chemotherapy-induced
cancer cell damage [26,27]. By contrast, subsequent gefit-
inib will not be expected to achieve its potential synergy
with chemotherapy if a tumor did not respond to chemo-
therapy. Considering that the combination effect is sched-
ule-dependent, the rationale would be to administer the
gefitinib when chemotherapy is inducing or has induced
maximum tumor damage. Thus, in the present trial, only
patients with an MR or PR to chemotherapy were
included. Although one patient (3%) achieved a CR, the
sequential administration of gefitinib following a minor
or partial response to chemotherapy did not appear to
result in a greater RR than with single agent gefitinib. The
TTP and OS achieved using this sequential administration
strategy were comparable to those attained with combina-
tion chemotherapy regimens including paclitaxel plus cis-
platin (PC), gemcitibine plus cisplatin (GC) or navelbine
plus cisplatin (NP).
It has been reported that the overall RRs of PC, GC and NP
regimens are 30% to 40% in chemotherapy-naïve
patients, with CRs of less than 5%. The RR was lower in
second-line settings, varying from 6% to 21% [28,29].
Clinical study demonstrated that a significant proportion
of patients with advanced NSCLC have subjective symp-
toms, such as anorexia, weight loss, and impairment of
performance status [28]. Since QOL is a major end point
of second-line chemotherapy, severe toxicity is not accept-
able in this setting. However, grades 3 and 4 toxicities
were frequently reported in the PC, GC or NP regimens
[3,19]. Based on our clinical experience, response is usu-
ally apparent after the initial two to three cycles of chem-
otherapy. This means that subsequent chemotherapy of
three to four cycles, 2.3 to 3.0 months, is only to consoli-
date the clinical response obtained. These regimens yield
median duration of response of 4 to 6 months in
advanced patients who have thus been experiencing
chemotherapy with about 50% to 70% median duration
of response and only 30% remission time free of chemo-
therapy and its associated toxicity.
Conclusion
Although the optimal schedule of gefitinib in advanced
NSCLC has not yet been defined, the present study sug-
gests that sequential administration of gefitinib following
chemotherapy is a promising approach in the manage-
ment of advanced NSCLC. A randomized trial to identify
this sequential schedule of administration of gefitinib and
chemotherapy is required to ensure better clinical efficacy
in the treatment of advanced NSCLC.
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Table 4: Drug-Related Adverse Events in 33 Assessable Patients
Adverse Event Grade 1 Grade 2 Grade 3 Grade 4
No. % No. % No. % No. %
Skin
R a s h 3 9 . 1 39 . 113 . 00 0
Pruritus 2 6.1 2 6.1 0 0 0 0
Dry skin 1 3.0 0 0 0 0 0 0
Acne 1 3.0 1 3.0 0 0 0 0
Digestive
Diarrhea 5 15.2 1 3.0 0 0 1 3.0
Nausea 2 6.1 1 3.0 1 3.0 0 0
V o m i t i n g 0 0 001 3 . 0 00
A n o r e x i a 26 . 1000000
Costiveness 1 3.0 0 0 0 0 0 0
Metabolic
I n c r e a s e d  A L T13 . 0000000
I n c r e a s e d  A S T13 . 0000000
Table 3: Symptom Improvement in 33 Assessable Patients
Response Symptom Improvement
No. %
CR+PR 1+5 18.2
SD 12 36.3
PD 0 0
Total 18 54.5BMC Cancer 2006, 6:288 http://www.biomedcentral.com/1471-2407/6/288
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